Breaking News

iBio Advances Lead COVID Vax Program IBIO-202

Moving forward with IND-enabling challenge studies for its second-generation vaccine candidate targeting the nucleocapsid (“N”) protein.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

iBio, Inc., a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System, shared an update on its lead COVID-19 vaccine program, IBIO-202.   iBio recently received the U.S. FDA response to its pre-investigational new drug (IND) package for IBIO-202 and is moving forward with IND-enabling challenge studies for its second-generation vaccine candidate targeting the nucleocapsid (“N”) protein and plans to file an IND application before the end ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters